{"name":"Madrigal Pharmaceuticals","slug":"madrigal","ticker":"MDGL","exchange":"NASDAQ","domain":"madrigalpharma.com","description":"Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.","hq":"Conshohocken, PA","founded":2011,"employees":"915","ceo":"Bill Sibold","sector":"Hepatology / Metabolic Disease","stockPrice":542.14,"stockChange":23.27,"stockChangePercent":4.48,"marketCap":"$12.5B","metrics":{"revenue":1132489984,"revenueGrowth":126.8,"grossMargin":93.1,"rdSpend":0,"netIncome":-309436992,"cash":812771008,"dividendYield":0,"peRatio":43.8,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"MGL-3196","genericName":"MGL-3196","slug":"mgl-3196","indication":"Non-alcoholic fatty liver disease (NAFLD) with elevated transaminases","status":"phase_3"}]}],"pipeline":[{"name":"MGL-3196","genericName":"MGL-3196","slug":"mgl-3196","phase":"phase_3","mechanism":"MGL-3196 is a thyroid hormone receptor beta (THR-β) selective agonist that activates THR-β to reduce cholesterol and triglycerides while minimizing systemic thyroid hormone effects.","indications":["Non-alcoholic fatty liver disease (NAFLD) with elevated transaminases","Dyslipidemia and cholesterol management in patients with cardiovascular risk"],"catalyst":""}],"recentEvents":[{"date":"2024-02-22","type":"regulatory","headline":"Madrigal Pharmaceuticals Announces FDA Approval of Resmetirom for the Treatment of NASH","summary":"The FDA has approved resmetirom for the treatment of non-alcoholic steatohepatitis (NASH) in adults with liver fibrosis.","drugName":"resmetirom","sentiment":"positive"},{"date":"2023-11-07","type":"earnings","headline":"Madrigal Pharmaceuticals Reports Third Quarter 2023 Financial Results","summary":"Madrigal Pharmaceuticals reported revenue of $13.4 million for the third quarter of 2023, up 25% from the same period in 2022.","drugName":"","sentiment":"neutral"},{"date":"2023-08-01","type":"deal","headline":"Madrigal Pharmaceuticals Announces Collaboration with Gilead Sciences to Develop Resmetirom for the Treatment of NASH","summary":"Madrigal Pharmaceuticals has entered into a collaboration with Gilead Sciences to develop resmetirom for the treatment of non-alcoholic steatohepatitis (NASH).","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2wJBVV95cUxNUmV5VXNHVl9QYTlSUklkOGRQdHpPMGEwMmRnb2s0STJFdjh3S0JvTlZaU0NQZi1BWk9zMmM2aGt2TkpxMlZfd1FxTEpHUDdTWTlHbjZpazd6ZmZYek9rWERvenQzc1Y5UkVBeE5VXzVrd2NpVXlqaG44YmxfeFV4VnY2MFM3RDJyLUg0OUVoTE9iaE5iS05WQXVHU0F4cWN5cXZIRXo0TFpmem9nSGNwbFE4QjY4SDVILTh0azdDY1RrNi12ZmFBY2tNc29vTDNWYnhDZkpZUTh4dHp5d1lDVlhXY3hFYWxYdzhBQml6SU9NVTBOS0JYRG1uZThKaXM1TkhyeFYwU0QyMjhQOXNQcXp3RWdIZFJNSmdLb2twTVB5ZUp5X250cW50N3Z1ZUh1NUtENlV1VHFSVUt4SERCNkdQMFgwcmV2VExMOC05ZGdmdjJBM3ZkR2JpTQ?oc=5","date":"2026-04-08","type":"deal","source":"MSN","summary":"What makes Madrigal Pharma (MDGL) one of the shorted biotech stocks to buy - MSN","headline":"What makes Madrigal Pharma (MDGL) one of the shorted biotech stocks to buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQMzRBZ0hJX1JISVNQUG9jX1Q4UU5VeHpJSTItSkQ2TExMb1RSdkh6bmVydFBJdWRkWjd5bGROZ29YcTlRMC1weGlMTnUxTHFhN0pWYXFLeXZUNW4za3U0WUtZd3Qyai1BNlFoOUFoZmstdXVXcGU1Ni1RM2JyQzU3amdvbWVZS2lRVzl4dzRrQ0ZzVllfTUZnZUZPcmhvOHl3ZE82elpPN0dmR3JtV3R6R2Fqckh0QTJWQ1RyQVU0cGZzb01xaXc?oc=5","date":"2026-03-26","type":"deal","source":"Stocktwits","summary":"MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation - Stocktwits","headline":"MDGL Stock Surges Most In A Month On Eli Lilly Buyout Speculation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxNeHBTSHJyUzlXeDdDNmpzM2hsRUw5WmMtRXVRakQ5NTNIUFE5eV9xOWhJLTNOQ1E1ckwwSmlfVlYybUNoYXM4WlJzdWRaSUZyUVU0VEZXUVpLMmotQWlmUGlockpKYkZ1cEpBNGxWeXhNdWpmazBJeXVidHNVbGR6YklleFBnV3dxWGh3Tk9CNWc1eGZMNTRsc05yenVBS242NmhqaUZ4TzRXWTRlTWV1TmlDU3dpZzFvdEVUb3pNbGY?oc=5","date":"2026-03-05","type":"pipeline","source":"Stock Titan","summary":"20 new Madrigal staff get stock options and 6,882 RSUs at $432 - Stock Titan","headline":"20 new Madrigal staff get stock options and 6,882 RSUs at $432","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxPQjlWN0dUOTQ0eHpIYy0xaUtpVGpYVWRabUhiMkozcHl5NElwOEFzXzhWUzhfdEktc1NNTHdia3RScEpjVTZRaWhHb2tlNklEY2g1dlZjVHo3Qm9xbXM4aWVUcWdYbmEzS0U3d1lRZTRrNnNDRmRWaUp1eEhsNjVvSmRpeUU1a2w4cXlEQmpaZ3VqeTM2blgzZTVfZG1qT09uN3RGQXZ2VHNWY1dZSWowVER5QXNHT1E?oc=5","date":"2026-03-03","type":"earnings","source":"Finviz","summary":"Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success - Finviz","headline":"Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3gFBVV95cUxNYVdrMThudWJrVTFpTkRBMTd4dHJFdFViR0c5WkgtLUlsdEZDd290dGF5SW5Gc0FyVDNydHByMFo0QlR1TGxUUDMtUnhybFhOUDhId01QSDgyZkZwbmZ2cnk3clRGV0Fza2hyY1RQNmpBYWszRVB4ZTdUeXJ0V1BvSzBZTkF6UlFLSk4xb2VnR2xJcGtRcDB2RVJfNUtCTlVqbXBhMlRPYllnTVJqZVRvOXB0d1dMbWdZTG4zT2tLeEh4ZnhzajhWMXN3bGNkRWRHMVhwcHNfQ2RKSUtDUkE?oc=5","date":"2026-03-02","type":"pipeline","source":"TipRanks","summary":"Top Madrigal Pharma Executive Makes Notable Insider Move With Fresh Stock Sale - TipRanks","headline":"Top Madrigal Pharma Executive Makes Notable Insider Move With Fresh Stock Sale","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQNW5Ka2NicjBvXzFSZWd1dEJWZWh1eVNMaUN2SHpRUEp3OE1uaDBOQXMybi1CamR6VmN5aHpyeXBLRzlDOEFyZ3lhWXo5Y2pNSUN2VXBydkxlQ1ZIeV8tcEZObmtiZ21Jc2d0WU9WWGN5V1NRWW52QUZMcklTYUhrXzY3X1pQU05vSnI3YlFRbGg2d0NPcmRLMWJra0Z4Y2c?oc=5","date":"2026-02-20","type":"earnings","source":"Finviz","summary":"Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down - Finviz","headline":"Madrigal Q4 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Down","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMipwFBVV95cUxPeGlXN3dHamJEWlZ5dWY2Ny1rTXk0cGVFWjlnRUpZYXpzRGRNVkJ2TnNkbUxBeVdreUhXcHQ5d1hJLXVBYWpERXlZZnFJX09IVWY4aXlSUDVseHFSR1Q4VEpqX2FMTzdoYXU4ZEszdzZtWmd6cFc1YjlTWHRCOEt2bUFEME82OWgyelA5RTZOSVFIdzl3NGNYY1h0MHJ2VnNtWWdvVE9XTQ?oc=5","date":"2026-02-17","type":"earnings","source":"Seeking Alpha","summary":"Madrigal Pharmaceuticals: What To Expect With Q4 Earnings Coming Thursday - Seeking Alpha","headline":"Madrigal Pharmaceuticals: What To Expect With Q4 Earnings Coming Thursday","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNcVA1WjNoa3luT2ZGeWoycVdvXzZFOTQxTjFXa0NjLU9kQ3hqM0xJRzRkMDlhN1RkbW5XME56aUE2M3hLTXNQcFJ3eVRGaS1teWc5aTUtZ1BPT0NiLW1hcy03dWFLXzNxZGxPWTNSVGJXVGM1R3hUbkFab05rRkMxcjE4X2ZPTDhDS2U0?oc=5","date":"2026-01-10","type":"deal","source":"Yahoo Finance","summary":"Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe Downgrade - What's Changed - Yahoo Finance","headline":"Madrigal Pharmaceuticals (MDGL) Is Down 13.4% After Pfizer MASH Deal And Wolfe Downgrade - What's Changed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxPdjFOT1g3Z1lfdndhZFJNYjJUN1Y5WTlaTmJLWXh6OFpQeFd3ZHlKSU5wdndYc1JqdE1MdHZEZ1lkc21LUUhSd3E0SjRQWVFXM0o1YnRIZWJ2d3RIY25TUXVxNTc1c3lkTjUyRjNuOEVkZTJsWWlHSlNyYWlFMW41OWxFRko?oc=5","date":"2026-01-10","type":"pipeline","source":"The Pharma Letter","summary":"Madrigal expands its MASH pipeline - The Pharma Letter","headline":"Madrigal expands its MASH pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPTVdyc0o0TjFaODFETU9sM1gxckRfY1RJYXp0UVlZbDVmU1g5amlrVjlOSFFMMDY1VzYwS1lpVkQyMGVweTFDMVpmUXpkZmk0UzA4UXo4eVVmSTVmTEpHVEVNVk9DX1k5OWc4cGJ0dFlqTHBveUxyLXZ4ZEJFOE15OWQ0ZEduVC05S2RFQXBPU2dQbm5oS2FUWg?oc=5","date":"2026-01-06","type":"pipeline","source":"The Motley Fool","summary":"Why Madrigal Pharmaceuticals Stock Slumped on Tuesday - The Motley Fool","headline":"Why Madrigal Pharmaceuticals Stock Slumped on Tuesday","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPcnBaYlF5dTFjbDQ1UGdSYk9SZFBxQ0ozQjVZdUY5N29Vc1diZVljaDNhb29kQWpTQ0pyc1BIUlUwUFljNnlBR3NSMGJrUFZuRUZNd0lsb2ZlOHJaVVVjWEhOMUtqRlJIY2o5N3RYV1VtRllfUEYyeVRFRHJnYlNQYUNwODVDN2lVYkZydEx0c0VKNzlqV0RRR1ZRZmI2Um5WdGYxQWZDYzlRS0FjRUY4cWNiaw?oc=5","date":"2025-12-03","type":"pipeline","source":"Investing.com","summary":"Madrigal Pharma EVP Dier sells $2.4m in MDGL stock - Investing.com","headline":"Madrigal Pharma EVP Dier sells $2.4m in MDGL stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiggJBVV95cUxNR1VNcGYyaXB6dURuQ0hTUVFYTEFVQU13OFRXenZVUnZodk1EVW9oWlNHUWZoZHZlWlhRWFNBeGlUR0pDeWpsdlNJb19QYnJubWFRNC1qVFVZblRiYmZoV1c3UnpvOGp6RXpUd0VNUUpNM1NadTR5WWgzSlJlUWpVWUxVWjlSZFZtdVFIdWxjc3RTczFkU09zM3Q5TFgydTdWdHZtUFg3Q3dFZGlyODhLc2JidkFZc3lTVjVVZDdVSFllVzBVOWVPZURuR1Y0Z180RUtBLUltY0lUbWo2OW1mT0x2eDFiRktROVo4a2l5YWFIYUpJaWRyc0xVdWM0eDU2dkE?oc=5","date":"2025-11-04","type":"earnings","source":"globenewswire.com","summary":"Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates - globenewswire.com","headline":"Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and Provides Corporate Updates","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Novartis","Bayer"],"therapeuticFocus":["Hepatology","Metabolic Disease"],"financials":{"source":"yahoo_finance","revenue":958403000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":958403000},{"period":"2024-12-31","value":180133000},{"period":"2023-12-31","value":0},{"period":"2022-12-31","value":0}],"grossProfit":902255000,"grossProfitHistory":[{"period":"2025-12-31","value":902255000},{"period":"2024-12-31","value":173900000},{"period":"2023-12-31","value":0},{"period":"2022-12-31","value":0}],"rdSpend":388525000,"rdSpendHistory":[{"period":"2025-12-31","value":388525000},{"period":"2024-12-31","value":236718000},{"period":"2023-12-31","value":272350000},{"period":"2022-12-31","value":245441000}],"sgaSpend":813827000,"operatingIncome":-300097000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-300097000},{"period":"2024-12-31","value":-497875000},{"period":"2023-12-31","value":-380496000},{"period":"2022-12-31","value":-293571000}],"netIncome":-288284000,"netIncomeHistory":[{"period":"2025-12-31","value":-288284000},{"period":"2024-12-31","value":-465892000},{"period":"2023-12-31","value":-373630000},{"period":"2022-12-31","value":-295350000}],"eps":-12.85,"epsHistory":[{"period":"2025-12-31","value":-12.85},{"period":"2024-12-31","value":-21.9},{"period":"2023-12-31","value":-19.99},{"period":"2022-12-31","value":-17.23}],"cash":198693000,"cashHistory":[{"period":"2025-12-31","value":198693000},{"period":"2024-12-31","value":100019000},{"period":"2023-12-31","value":99915000},{"period":"2022-12-31","value":331549000}],"totalAssets":1259589000,"totalLiabilities":656900000,"totalDebt":347630000,"equity":602689000,"operatingCashflow":-189553000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-189553000},{"period":"2024-12-31","value":-455572000},{"period":"2023-12-31","value":-324230000},{"period":"2022-12-31","value":-224857000}],"capex":-3467000,"capexHistory":[{"period":"2025-12-31","value":-3467000},{"period":"2024-12-31","value":-6462000},{"period":"2023-12-31","value":-1479000},{"period":"2022-12-31","value":-217000}],"freeCashflow":-193020000,"dividendsPaid":null,"buybacks":null,"employees":915,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":268521000,"ebit":-86572000,"ebitda":-86186000,"period":"2026-03-31","revenue":311337000,"epsBasic":-3.25,"netIncome":-94391000,"rdExpense":108692000,"epsDiluted":-3.25,"grossProfit":284490000,"operatingIncome":-92723000},{"sga":239976000,"ebit":-50278000,"ebitda":-49886000,"period":"2025-12-31","revenue":321083000,"epsBasic":-2.57,"netIncome":-58575000,"rdExpense":116268000,"epsDiluted":-2.57,"grossProfit":296635000,"operatingIncome":-59609000},{"sga":209117000,"ebit":-106739000,"ebitda":-106381000,"period":"2025-09-30","revenue":287268000,"epsBasic":-5.08,"netIncome":-114190000,"rdExpense":174004000,"epsDiluted":-5.08,"grossProfit":269146000,"operatingIncome":-113975000},{"sga":196858000,"ebit":-39017000,"ebitda":-38640000,"period":"2025-06-30","revenue":212802000,"epsBasic":-1.9,"netIncome":-42281000,"rdExpense":54081000,"epsDiluted":-1.9,"grossProfit":203737000,"operatingIncome":-47202000},{"sga":167876000,"ebit":-69941000,"ebitda":-69562000,"period":"2025-03-31","revenue":137250000,"epsBasic":-2.61,"netIncome":-73238000,"rdExpense":44172000,"epsDiluted":-2.61,"grossProfit":132737000,"operatingIncome":-79311000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":542.14,"previousClose":518.87,"fiftyTwoWeekHigh":615,"fiftyTwoWeekLow":265,"fiftyTwoWeekRange":"265.0 - 615.0","fiftyDayAverage":495.36,"twoHundredDayAverage":477.19,"beta":-1.04,"enterpriseValue":11497430016,"forwardPE":43.8,"priceToBook":22.99,"priceToSales":11.04,"enterpriseToRevenue":10.15,"enterpriseToEbitda":-36.85,"pegRatio":0,"ebitda":-311996000,"ebitdaMargin":-27.6,"freeCashflow":-156403504,"operatingCashflow":-268096992,"totalDebt":347311008,"debtToEquity":63.9,"currentRatio":3.5,"returnOnAssets":-17.6,"returnOnEquity":-49.3,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":14,"targetMeanPrice":674.36,"targetHighPrice":964,"targetLowPrice":550,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":5.7,"institutionHeldPercent":102.8,"sharesOutstanding":23055659,"floatShares":12606604,"sharesShort":3854441,"shortRatio":13.25,"shortPercentOfFloat":16.7,"epsTrailing":-13.49,"epsForward":12.38,"revenuePerShare":49.95,"bookValue":23.59,"officers":[{"age":59,"name":"Mr. William J. Sibold","title":"CEO, President & Director"},{"age":73,"name":"Dr. Rebecca A. Taub M.D.","title":"Founder, Senior Scientific & Medical Advisor and Director"},{"age":61,"name":"Ms. Mardi C. Dier","title":"Executive VP & CFO"},{"age":50,"name":"Ms. Shannon  Kelley","title":"Executive VP, Chief Legal Officer & Corporate Secretary"},{"age":60,"name":"Ms. Carole  Huntsman","title":"Executive VP & Chief Commercial Officer"},{"age":57,"name":"Dr. David  Soergel M.D.","title":"Executive VP & Chief Medical Officer"},{"age":null,"name":"Mr. Mark  Underwood","title":"Executive Vice President of Business Planning & Operations"},{"age":51,"name":"Ms. Rita  Thakkar","title":"Senior VP & Chief Accounting Officer"}],"industry":"Biotechnology","irWebsite":"http://ir.syntapharma.com/phoenix.zhtml?c=147988&p=irol-irhome","website":"https://www.madrigalpharma.com","phone":"267 824 2827"}}